Enhancing liver cancer treatment with immune therapy and radiation
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors
['FUNDING_R01'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-11081783
This study is exploring a new way to help cancer patients with liver tumors by using a combination of targeted radiation and a special immune therapy, hoping to boost the body's immune response and improve treatment outcomes for both liver and other tumors.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-11081783 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating liver metastasis in cancer patients by combining liver-directed radiotherapy with immune checkpoint blockade therapy. The study focuses on enhancing the immune response in the liver using a substance called entolimod, which activates specific immune pathways. By improving the effectiveness of these treatments, the goal is to achieve better control over both irradiated liver tumors and non-irradiated tumors elsewhere in the body. Patients may have the opportunity to participate in trials that assess the safety and efficacy of this combined treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with liver metastasis from various cancers who are undergoing or considering liver-directed radiotherapy and immune checkpoint blockade.
Not a fit: Patients with primary liver cancers or those who do not have liver metastasis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with liver metastasis by enhancing the effectiveness of existing therapies.
How similar studies have performed: Previous studies have shown promising results with similar immune-modulating therapies, indicating potential for success in this novel approach.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRACKETT, CRAIG M. — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: BRACKETT, CRAIG M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Radiation Syndrome